Fact CheckerSign in

NCT06827834Recruiting

Spinal Cord Monitoring in Multiple Sclerosis

A Prospective Longitudinal Study of Spinal Cord Lesions in Multiple Sclerosis: MRI Monitoring and Prognostic Factors for Active Disease

Source: ClinicalTrials.gov · Last updated 14 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system and the most common cause of non-traumatic neurological disability in young adults. Magnetic resonance imaging (MRI) is the most important paraclinical investigation used in the diagnosis and monitoring of the disease. In the past years, spinal cord MRI has improved significantly and has become an important part of the diagnostic workup for MS. Presently, follow-up imaging of the spinal cord is only performed when spinal cord related symptoms occur. However, there is increasing evidence that asymptomatic spinal cord lesions can occur, independently of brain disease activity. Despite these cord lesions being asymptomatic, they impact disability accrual in the long term. Although this might be an imaging marker for monitoring and treatment, it is not yet applied in the clinical setting. The investigators will prospectively collect spinal cord MRI data (in addition to routine brain MRI), and blood-based biomarkers (plus cerebral spinal fluid markers, if available), in recently diagnosed MS patients, to address the following research questions: * What is the incidence of asymptomatic spinal cord lesions in patients commencing DMT? * And in the absence of radiological progression on brain imaging, how frequently do asymptomatic spinal cord lesions occur? In other words, how often is disease activity solely proven by spinal cord MRI and what is the number-needed-to-scan? * A secondary objective is to investigate which patients are predisposed to developing new spinal cord lesions during follow-up in the early stages of the disease. For this question, factors such as cerebrospinal fluid (CSF) profiles, B-cell composition in blood, soluble blood markers, and clinical features will be focused on.

Status (registry)
Recruiting
Study type
Observational
Enrollment
155 (estimated)
First submitted
27 Jan 2025
Start date
6 Aug 2024
Primary completion date
1 Jun 2028
Lead sponsor
Zuyderland Medisch Centrum
NCT number
NCT06827834

What you commit to

  • Study type: Observational
  • Planned participants: 155
  • From 6 Aug 2024 to the primary completion date, 1 Jun 2028
  • 5 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Patients who presented first clinical event more than five years ago
  • Patients who have already started DMT
  • Patients who are incapable of giving informed consent
  • Patients who are unable to undergo local MRI scan, due to for instance
  • Physical problems, for instance due to size/obesity (not fitting in regular MRI scanner), not being able to lie flat for extended periods of time (e.g. due to pain, shortness of breath)
  • Due to claustrophobia
  • Patients who have contraindications for MRI scan, for instance
  • Due to MRI-unsafe or non-compatible implanted material/devices, such as pacemakers or ocular metal splinters
  • Patients who are pregnant at inclusion

Who the study is looking for

  • Patients between 18 and 65 years old
  • Patients diagnosed with relapsing-remitting MS (≤5 years of first clinical event)
  • Treatment-naïve patients starting (currently in the Netherlands approved) DMT

Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (5)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Rijnstate
Coordinator of this site? Confirm its status
ArnhemNetherlandsNot yet recruiting
Albert Schweitzer Ziekenhuis
Coordinator of this site? Confirm its status
DordrechtNetherlandsRecruiting
Zuyderland Medisch Centrum
Coordinator of this site? Confirm its status
GeleenNetherlandsRecruiting
Erasmus MC
Coordinator of this site? Confirm its status
RotterdamNetherlandsNot yet recruiting
Jeroen Bosch Ziekenhuis
Coordinator of this site? Confirm its status
's-HertogenboschNetherlandsNot yet recruiting

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.